MTOR and non-small cell lung carcinoma: In NSCLC cells, the ROS inhibitors also induced naringenin-reduced p62 expression, decreased the LC3II/LC3I ratio (Figure 5B and S8A), and reversed naringenin-induced AMPKα phosphorylation and naringenin-suppressed mTOR phosphorylation (Figure 5C and S8B).